Wei Zuo

Tongji University, China

Wei Zuo  is  Full  Professor  and  Deputy  Director  of Tongji  Stem  Cell  Center, Tongji  University, Shanghai, China. He is also the Scientific Founder of Regend Therapeutics and Vice-President of Chinese Cell & Gene Therapy Society. Zuo  has  dedicated  most  of  his scientific  activities to translational medicine in lung and kidney field. Following his early work on murine airway stem cell  culture  and   intrapulmonary  transplantation   (Nature.  2015),  Zuo  was  first  to  develop pharmaceutical-grade   P63+   human   airway   basal   stem   cell   culture  and  intrapulmonary transplantation for lung tissue regeneration (Nature Communications, 2025; Science Advances, in press). He led a series of first-in-class NMPA-approved autologous basal stem cell therapy clinical trials to treat severe pulmonary conditions including COPD, IPF and bronchiectasis (Science Transl Med. 2024; Cell Rep Med. 2024; eLife.2024). Currently these lung regeneration clinical trials have completed the Phase II stage, which demonstrates great potential in repair of injured human lung tissue and recovery of lung gas exchange function. Zuo also developed an autologous renal SOX9+ progenitor cell -based kidney regeneration therapy, which has been approved by NMPA for clinical trials in 2025.